Were the Vaxcyte (PCVX) COO’s June 2026 share sales made under a trading plan?

Yes. The filing notes the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. Such plans pre-schedule trades, making the timing more routine and less tied to short-term information or discretionary decisions.

COO of Vaxcyte (NASDAQ: PCVX) sells 2,250 shares in pre-set plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vaxcyte, Inc. Chief Operating Officer Jim Wassil reported open-market sales of a total of 2,250 shares of common stock on June 1, 2026, at weighted-average prices around $50 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025.

After these sales, Wassil continues to hold about 158,000 shares of Vaxcyte common stock directly, indicating that the trades represent a small portion of his overall position and appear to be routine, pre-planned portfolio management rather than a change in fundamental outlook.

Insider Trade Summary 10b5-1

Net Seller: 2,250 shares ($111,416)

Net Sell 2 txns

Insider Wassil Jim

Role CHIEF OPERATING OFFICER

Sold 2,250 shs ($111K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,949	$49.404	$96K
Sale	Common Stock	301	$50.257	$15K

Holdings After Transaction: Common Stock — 158,795 shares (Direct, null)

Footnotes (1)

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. The price reported is a weighted-average price. The shares were sold at prices ranging from $49.03 to $49.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $50.205 to $51.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 2,250 shares Weighted-average sale price (block 1): $49.404/share Weighted-average sale price (block 2): $50.257/share +1 more

4 metrics

Shares sold 2,250 shares Total common shares sold in open market on June 1, 2026

Weighted-average sale price (block 1) $49.404/share Common stock sales with prices from $49.03 to $49.93

Weighted-average sale price (block 2) $50.257/share Common stock sales with prices from $50.205 to $51.01

Shares held after transactions about 158,000 shares Direct holdings reported following June 1, 2026 sales

Key Terms

Rule 10b5-1 trading plan, weighted-average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported is a weighted-average price. The shares were sold at prices ranging from $49.03 to $49.93."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 04:59 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wassil Jim

(Last)

(First)

(Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS

CALIFORNIA

94070

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF OPERATING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		S⁽¹⁾		1,949	D	$49.404⁽²⁾	158,795	D
Common Stock	06/01/2026		S⁽¹⁾		301	D	$50.257⁽³⁾	158,494	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

2. The price reported is a weighted-average price. The shares were sold at prices ranging from $49.03 to $49.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. The price reported is a weighted-average price. The shares were sold at prices ranging from $50.205 to $51.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

	Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Vaxcyte (PCVX) report for COO Jim Wassil?

Vaxcyte’s COO Jim Wassil reported selling 2,250 shares of common stock in open-market transactions. The sales occurred on June 1, 2026, at weighted-average prices near $50 per share, as disclosed in a Form 4 insider trading report.

At what prices did the Vaxcyte (PCVX) COO sell shares on June 1, 2026?

Jim Wassil sold shares at weighted-average prices of $49.404 and $50.257 per share. Footnotes state individual trades occurred in ranges from $49.03 to $51.01, with full price breakdowns available upon request from the reporting person.

How many Vaxcyte (PCVX) shares did COO Jim Wassil retain after the reported sales?

After the reported sales, Jim Wassil continued to hold about 158,000 shares of Vaxcyte common stock directly. This indicates the 2,250 shares sold represent only a small fraction of his total reported holdings in the company.

What type of insider transaction code is shown in the Vaxcyte (PCVX) Form 4?

The Form 4 shows transaction code “S,” indicating sales in the open market or private transactions. Both entries are classified as non-derivative common stock sales, reflecting straightforward disposals of existing shares rather than option exercises or conversions.